Exposure, dental pulp

Summary

Exposure, dental pulp (MONDO:0020812) is a disease and 25 clinical trials. Top therapeutic interventions include diosmin, simvastatin, and calcium hydroxide. A subtype of dental pulp disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 25

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	exposure, dental pulp
Mondo ID	MONDO:0020812
MeSH	D003789
UMLS	C0011406
MedGen	41473
Is cancer (heuristic)	no

Also known as: DENT PULP EXPOSURE · Dental Pulp Exposure · EXPOSURE DENT PULP · Exposure of tooth pulp · PULP EXPOSURE DENT · Pulp Exposure, Dental

Disease family

This is a subtype of dental pulp disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › tooth disorder › dental pulp disorder › exposure, dental pulp

Related subtypes (6): pulp degeneration, dental pulp necrosis, pulp erosion, dental pulp calcification, pulpitis, secondary dentine

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Calcium Hydroxide	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 25.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE2/PHASE3	4
PHASE4	1
PHASE2	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04989036	PHASE4	COMPLETED	Biodentine Vital Pulpotomy in Immature Molars
NCT01468480	PHASE2/PHASE3	COMPLETED	Human Pulpal Response After Pulp Capping With Four Different Agents
NCT02492841	PHASE2/PHASE3	COMPLETED	Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth
NCT03838068	PHASE2/PHASE3	COMPLETED	Pulpotomy Technique Preserving Vitality of Traumatized Anterior Permanent Immature Teeth
NCT06171776	PHASE2/PHASE3	UNKNOWN	Evaluation of Conservative Management of Teeth With Deep Cavitated Carious Lesions
NCT02019563	PHASE2	COMPLETED	MTA/FS Pulpotomy for Vital Primary Incisors: A Randomized Controlled Trial
NCT07557290	PHASE1	NOT_YET_RECRUITING	Comparative Evaluation of Clinical and Radiographic Outcomes of Mustard Gel (Brassica Nigra) and Mineral Trioxide Aggregate (MTA) as Pulpotomy Agents in Deciduous Molars- A Randomized Controlled Trial
NCT05878158	EARLY_PHASE1	UNKNOWN	Simvastatin Versus MTA in Pulpotomy of Immature Permanent Molars
NCT05397964	Not specified	ENROLLING_BY_INVITATION	Retrospective Evaluation of the Results of Direct Pulp Capping Treatment
NCT05812053	Not specified	RECRUITING	Comparative Evaluation of Eggshell Powder in Primary Teeth Pulpotomy
NCT06946719	Not specified	ACTIVE_NOT_RECRUITING	Octenidine and Sodium Hypochlorite for Pulp Irrigation in Direct Pulp Capping
NCT07041905	Not specified	RECRUITING	Effects of Total and Selective Caries Removal - Requiring or Avoiding Vital Pulp Therapy - on Pulp Vitality and Postoperative Pain in Deep Carious Mature Permanent Teeth: A Split-Mouth Clinical Study
NCT07108738	Not specified	NOT_YET_RECRUITING	Pomegranate Peel Extract for Primary Molar Pulpotomy
NCT07130214	Not specified	ACTIVE_NOT_RECRUITING	The Effect of Genetic Polymorphisms on the Success of Vital Pulp Therapy
NCT00187850	Not specified	COMPLETED	The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy
NCT00812877	Not specified	COMPLETED	Pulp Capping With Two Different Agents
NCT02487329	Not specified	COMPLETED	The Effect of Laser Combined With Pulp-capping Agents on Direct Pulp Capping
NCT02789423	Not specified	COMPLETED	Clinical & Radiographical Evaluation of the Effect of Dycal & Biodentine in DPC in Primary Teeth
NCT03490422	Not specified	COMPLETED	Pulpotomy in Carious Permanent Mature Teeth: Pulp Survival and Risk Factors
NCT03631511	Not specified	COMPLETED	Histological Evaluation of Hard Tissue Formation After Direct Pulp Capping With RetroMTA
NCT04052685	Not specified	COMPLETED	Selective Removal to Soft Dentine vs Selective Removal to Firm Dentine for Deep Posterior Caries Lesions
NCT04330768	Not specified	UNKNOWN	Platelet Rich Fibrin(PRF) Injection for Treatment of Dental Pulp Exposure:Randomized Clinical Trial
NCT06402032	Not specified	COMPLETED	Clinical and Histological Evaluation of Hesperidin as a Direct Pulp Capping Material
NCT07231237	Not specified	TERMINATED	Clinical Study Evaluating Solventum™ Vitrebond™ Pulp Protect Liner/Base for Direct Capping of Pulpal Exposure
NCT07593508	Not specified	COMPLETED	Diode Laser-Assisted Direct Pulp Capping Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DIOSMIN	4	1
SIMVASTATIN	4	1
CALCIUM HYDROXIDE	3	3
HESPERIDIN	3	1